

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

September 13, 2004

Date of Report (date of Earliest Event Reported)

ISOLAGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

(State or Other Jurisdiction of
Incorporation or Organization)

001-31564

(Commission File No.)

87-0458888

(I.R.S. Employer Identification No.)

2500 Wilcrest, 5th Floor, Houston, Texas 77042

(Address of principal executive offices and zip code)

(713) 780-4754

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-

Item 1.01 Entry into a Material Definitive Agreement.

Effective September 13, 2004, Isolagen, Inc. ("Isolagen") and Dr. Kimberley Forbes-McKean entered into an employment agreement (the "Agreement") pursuant to which Dr. Forbes-McKean agreed to serve as Isolagen's Senior Vice President and Chief Technical Science Officer from September 20, 2004 until September 30, 2005. The Agreement provides for an annual salary of \$260,000, and, beginning in fiscal 2005, a merit-based bonus to be determined based upon mutually agreeable criteria. For fiscal 2004, Dr. Forbes-McKean shall receive a bonus of \$15,000. Under the Agreement, Dr. Forbes-McKean was issued a five-year option to purchase 175,000 shares of Isolagen common stock at an exercise price equal to the average market value of the common stock during the ten days preceding the issuance, which vests ratably on an annual basis over three years. The vesting provisions of the option would accelerate and Dr. Forbes-McKean would be entitled to a severance payment equal to her base salary for the greater of twelve months or the remainder of the term of the Agreement, if Dr. Forbes-McKean were terminated without "cause," or if Dr. Forbes-McKean were to terminate her employment with Isolagen for "good reason" (each of the terms as defined in the Agreement). During any period in which severance payments are being made, Dr. Forbes-McKean has agreed not to compete with Isolagen.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

- (a) Not applicable.
- (b) Not applicable.
- (c) (1) Commencing September 20, 2004, Isolagen appointed Dr. Kimberley Forbes-McKean to serve as Isolagen's Senior Vice President and Chief Technical Science Officer.

(2) Dr. Forbes-McKean, age 42, has not served with Isolagen in any capacity prior to her appointment as Senior Vice President and Chief Technical Science Officer. There are no familial relationships between Dr. Forbes-McKean and any director or executive officer of Isolagen. Since January 2000, Dr. Forbes-McKean served as Vice President of Global Dermatological Product Development and Commercialization at Aventis Global Dermatology a division of Aventis Pharmaceutical. From 1998 until January 2000, Dr. Forbes-McKean served as worldwide director of the dermatological product development at Dermik Laboratories, Inc. Dr. Forbes-McKean holds an B.S. in Chemistry from Union College, an M.S. in Chemistry from the University of Massachusetts, and a Ph.D. in Analytical Chemistry from the University of Massachusetts.

(3) See Item 1.01 for a discussion of the employment agreement between Isolagen and Dr. Forbes-McKean.
- (d) Not applicable.

Item 9.01 Financial Statements and Exhibits

- (a) Not applicable.
- (b) Not applicable.
- (c) Exhibits.

99.1 Press release dated September 16, 2004

[THE SIGNATURE PAGE FOLLOWS.]

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOLAGEN, INC.

Date: September 16, 2004

By: /s/ JEFFREY TOMZ

Jeffrey Tomz
Chief Financial Officer

QuickLinks

[SIGNATURE](#)

Thursday, September 16, 2004, 1:00 PM Eastern Time
Press Release

SOURCE: Isolagen, Inc.

**DR. KIMBERLEY FORBES-MCKEAN APPOINTED ISOLAGEN SENIOR VICE
PRESIDENT, CHIEF TECHNICAL SCIENCE OFFICER**

**Former Vice President of Global Dermatological Product Development for Aventis
Dermatology to join Isolagen**

HOUSTON—(PRNewswire)—September 16, 2004—Isolagen, Inc. (AMEX: ILE) is pleased to announce that its Board of Directors appointed Dr. Kimberley Forbes-McKean as Senior Vice President and Chief Technical Science Officer of Isolagen.

Dr. Forbes-McKean brings to Isolagen more than 15 years of experience in the pharmaceutical industry. She recently served as Vice President of Global Dermatological Product Development and Commercialization at Aventis Global Dermatology, a division of Aventis Pharmaceutical. At Aventis, Dr. Forbes-McKean orchestrated and directed all facets of dermatological development programs (aesthetic and prescription) leading to international commercialization, directed strategy for global regulatory activities for dermatology drugs and devices, and provided technical and scientific input for acquisition and licensing activities across a broad range of therapeutic conditions within dermatology, including aesthetics, wound healing and acne/rosacea. Prior to being named Vice President of Aventis Global Dermatology, Dr. Forbes-McKean held a variety of product development and research positions at Aventis and its predecessor companies.

As Senior Vice President and Chief Technical Science Officer of Isolagen, Dr. Forbes-McKean will oversee and transition the augmentation of certain facets of Product Development, including Project Management, Technical Scale-Up, Quality, Regulatory Affairs and Production.

Frank DeLape, Chairman of Isolagen in commenting on the hire said, "Dr. Forbes-McKean's broad experience in product development and commercialization in both aesthetic and prescription dermatologicals should prove to be very valuable considering our goals for Isolagen. We feel she is an excellent addition to help fulfill our objectives for achieving FDA approval of the Isolagen process and its ultimate broad-scale, world-wide commercialization."

About Isolagen, Inc.

Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

Isolagen's corporate headquarters are located in Houston, TX. For further information, please see www.isolagen.com.

Contact:

Jeffrey W. Tomz, Chief Financial Officer and Secretary—(713) 780-4754
Kate McNeil, Investors Contact, Investor Relations Group—(212) 825-3210
John Nesbett, Investors Contact, Investor Relations Group—(212) 825-3210
